Garofolo, Monia
Gualdani, Elisa
Giannarelli, Rosa
Aragona, Michele
Campi, Fabrizio
Lucchesi, Daniela
Daniele, Giuseppe
Miccoli, Roberto
Francesconi, Paolo
Del Prato, Stefano http://orcid.org/0000-0002-5388-0270
Penno, Giuseppe
Funding for this research was provided by:
Regione Toscana (D55E11002680005)
Article History
Received: 31 July 2019
Accepted: 1 November 2019
First Online: 16 November 2019
Ethics approval and consent to participate
: The local ethics committee approved the study protocol, and the study was carried out in accordance with Declaration of Helsinki. Each participant signed a written informed consent.
: Not applicable.
: MG has received travel grants from AstraZeneca and Novo Nordisk. MA has received speaker/advisory honoraria from Abbott Laboratories. FC has received travel grants from Novo Nordisk. GD reports past participation in advisory boards from AstraZeneca, Eli Lilly and Co and Novartis Pharmaceuticals. SDP reports past participation in advisory boards and/or receiving research grants from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, Sanofi, Servier, and Takeda Pharmaceuticals. GP has received travel grants and speaker/advisory honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck Sharp & Dohme, Mundipharma Pharmaceuticals, Novo Nordisk, and Takeda Pharmaceuticals. All other authors (EG, RG, DL, MR, and PF) declare that they have no competing interests.